Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction
Conditions
Brief summary
The aim of this study was to compare the efficacy and safety of mFOLFOX, mFOLFIRI and FOLFPTX as first-line treatment in AGC or EGJA.
Detailed description
In previous studies, we found that mFOLFOX(a Combination of Oxaliplatin, Fluorouracil), mFOLFIRI(a Combination of Irinotecan, Fluorouracil), FOLFPTX (a Combination of Paclitaxel, Fluorouracil) are active in patients with AGC or EGJA.This study is being done to find out which one has the best efficacy.
Interventions
DRUGFluorouracil
Fluorouracil was used as first line treatment with AGC.
DRUGOxaliplatin
Oxaliplatin was used as first line treatment with AGC.
DRUGIrinotecan
Irinotecan was used as first line treatment with AGC.
DRUGPaclitaxel
Paclitaxel was used as first line treatment with AGC.
DRUGcalcium levofolinate
Calcium levofolinate was used as first line treatment with AGC.
Sponsors
Fujian Cancer Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Age：18\ 70years. 2. Subjects with Histologically or cytologically confirmed advanced or metastatic gastric cancer or adenocarcinoma of gastroesophageal junction. 3. First-line treatment patients. 4. subjects with at least one measurable lesion as defined by RECIST (version 1.1). 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Survival expectation≥ 3 months. 7. No serious concomitant diseases(including heart,lung,liver jaundice or gastrointestinal obstruction and so on ). 8. Adequate organ functions defined as indicated below： （1）Adequate bone marrow function, defined as: (no blood transfusion within 14 days) 1. Hemoglobin (Hb)≥80g/L， 2. White blood count (WBC)≥3.5×109/L 3. Absolute neutrophil count (ANC)≥1.5×109/L， 4. Platelet count (PLT)≥75×109/L； （2）Adequate liver function, defined as: <!-- --> 1. Bilirubin ≤1.5×the upper limit of normal (ULN) 2. Alanine aminotransferase (ALT), or Aspartate aminotransferase (AST) ≤3.0×(ULN), Glutamyl transpeptidase(GGT)≤2.5×(ULN), (When liver metastases, ALT or AST and GPT \<5.0×(ULN)). 3. serum creatinine ≤1.0×（ULN）, or creatinine clearance \> 50 mL/min( calculated per the Cockcroft and Gault formula) 9. Females of childbearing potential must be a pregnancy test in 7 days before participating ( including serum or urine), and the results were negative, Females of childbearing potential must agree to use a highly effective method of contraception throughout the entire study period and for 8 weeks after study drug discontinuation. Male subjects must have had a successful vasectomy or they and their female partners must meet the criteria above (i.e.not of childbearing potential or practicing highly effective contraception throughout the study period and for 8 weeks after study drug discontinuation). 10. Subjects provided written informed consent before participating,Willing and able to comply with all aspects of the protocol.
Exclusion criteria
1. Females are lactating or pregnant at Screening or Baseline. 2. Patients with other active malignancy (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix). 3. Patients who have received previous pre- or post-operative chemotherapy or chemoradiation are ineligible if therapy was completed less than 6 months prior to study registration. Patients must have recovered from adverse events from any previous therapy. 4. Patients with brain or central nervous system metastases, including leptomeningeal disease. 5. Significant cardiac disease as defined as:unstable angina, New York Heart Association (NYHA) grade II or greater, congestive heart failure, history of myocardial infarction within 6 months Evidence of bleeding diathesis or coagulopathy. 6. History of a stroke or CVA within 6 months. 7. Inability to comply with study and/or follow-up procedures. 8. Patients with any other condition that in the opinion of the investigator would preclude his/her participation in a clinical study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | 24 months | — |
| Adverse Event（AE） | 35 months | NCI CTC 4.03 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | 24 months | — |
| Disease Control Rate (DCR) | 24 months | — |
| Overall Survival (OS) | 35 months | — |
| Quality of Life (QoL) | 35 months | Use the validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 \[EORTC QLQ-C30\]. |
Countries
China
Contacts
Primary ContactJianwei Yang
Backup ContactSha Huang
Outcome results
None listed